GSK to acquire Chimagen trispecific T cell‑engager for multiple myeloma
- Trispecific TCE engages T cells and two validated tumour antigens.
- Programme expected to enter Phase I clinical trials in 2027.
- GSK acquires full global rights with deal value up to $750 million.
- Deal builds on prior GSK–Chimagen agreement for CMG1A46 (dual CD19/CD20 TCE).
Deal overview
GSK has agreed to acquire a trispecific T cell‑engager (TCE) programme from Chimagen Biosciences, gaining full global rights to the asset. The agreement includes an upfront payment and success‑based development and commercial milestones, with a total potential value of up to $750 million, subject to customary closing conditions.
Asset profile and rationale
The Chimagen candidate is a trispecific TCE that binds T cells while simultaneously targeting two validated tumour‑associated antigens. It is positioned to deliver deeper and more durable responses and to improve tolerability versus existing TCEs, aiming to enable broader and earlier use in multiple myeloma treatment.
Clinical timeline
GSK plans to advance the programme into Phase I clinical trials in 2027.
Strategic context
The acquisition complements GSK’s blood‑cancer portfolio and follows a prior agreement between the companies for CMG1A46, a dual CD19/CD20 TCE currently in Phase I for B‑cell malignancies and B‑cell‑dependent autoimmune disorders. The US TCE market for multiple myeloma is projected to exceed $10 billion by 2032, and multiple myeloma accounts for roughly 180,000 new global diagnoses annually.
Source: GSK
